• Users Online: 835
  • Print this page
  • Email this page

  Reader Comments

Year : 2022 | Volume:  5 | Issue Number:  3

CORRIGENDUM

Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study



Add Your Comments
 
No one has added comments on this article. Click here to add your remarks


 

Back To Article